Effect of Combined Low Dose Human Gonadotropic Hormone, Follicle Stimulating Hormone, and Testosterone Therapy (LFT Regimen) Versus Conventional High Dose Human Gonadotropic Hormone and Follicle Stimulating Hormone on Spermatogenesis and Biomarkers in Men With Hypogonadotropic Hypogonadism
Authors' conclusion
A reasonable approach to induce fertility in male CHH is to initiate combination therapy using FSH, low-dose hCG targeting AMH <6.9 ng/ml, along with T to achieve normal range. Monitoring AMH could serve as a proxy indicator of spermatogenesis.
Study context
- Population
- Men with congenital hypogonadotropic hypogonadism (CHH)
- Participants
- 30 men
- Comparison
- LFT regimen vs conventional high-dose hCG + follicle stimulating hormone (FSH)
- Primary endpoint
- Percentage of individuals who achieved spermatogenesis
Methodological detailsopen-label, pilot, Conducted June 2020 to December 2021
- Open-label
- Pilot
- Conducted June 2020 to December 2021
Primary result
As reported in the abstract
Achievement of spermatogenesis
- No difference in achieving spermatogenesis between the two groups
- Between LFT regimen and Conventional therapy: P = 0.204
Further findings
| Outcome | P value |
|---|---|
| Median time to spermatogenesisSimilar | P = 0.248 |
| Median plasma AMH at spermatogenesisNonsignificant | P = 0.298 |
| Median plasma Inhibin B at spermatogenesisComparable | P = 0.488 |
Spermatogenesis achieved, all patients
- Achieved spermatogenesis
- 23 (76.7%)
- Median time to spermatogenesis
- 12 (9-14.9) months
Original publication
Effect of Combined Low Dose Human Gonadotropic Hormone, Follicle Stimulating Hormone, and Testosterone Therapy (LFT Regimen) Versus Conventional High Dose Human Gonadotropic Hormone and Follicle Stimulating Hormone on Spermatogenesis and Biomarkers in Men With Hypogonadotropic Hypogonadism. Endocr Pract. Published 25 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →